ctDNA variant-specific differences as potential mPDAC prognostic biomarker – PICI
Parker Institute for Cancer Immunotherapy (PICI) shared a post on X about a recent paper titled “Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma” published in Nature Communications. .
Authors: Jacob E. Till, Lee McDaniel, Changgee Chang, Qi Long, Shannon M. Pfeiffer, Jaclyn P. Lyman, Lacey J. Padrón, Deena M. Maurer, Jia Xin Yu, Christine N. Spencer, Pier Federico Gherardini, Diane M. Da Silva, Theresa M. LaVallee, Charles Abbott, Richard O. Chen, Sean M. Boyle, Neha Bhagwat, Samuele Cannas, Hersh Sagreiya, Wenrui Li, Stephanie S. Yee, Aseel Abdalla, Zhuoyang Wang, Melinda Yin, Dominique Ballinger, Paul Wissel, Jennifer Eads, Thomas Karasic, Charles Schneider, Peter O’Dwyer, Ursina Teitelbaum, Kim A. Reiss, Osama E. Rahma, George A. Fisher, Andrew H. Ko, Zev A. Wainberg, Robert A. Wolff, Eileen M. O’Reilly, Mark H. O’Hara, Christopher R. Cabanski, Robert H. Vonderheide and Erica L. Carpenter.
“New study in Nature Communications from a team including University of Pennsylvania PICI Investigators Dr. Robert Vonderheide, Dr.Erica Carpenter and PICI Senior Director of Clinical Research Dr. Chris Cabanski shows ctDNA variant-specific differences as potential mPDAC prognostic biomarker.”
Source: PICI/X